Shifts in market dynamics are challenging the pharmaceutical industry from increasing pricing pressures, the rise of generic and niche products, increasing outsourcing demand and market consolidation, to name a few. A&M helps pharmaceutical companies across their strategic and operational priorities by cutting complexity, accelerating execution and implementing change. A&M’s first-class professionals work with pharmaceutical companies to navigate through this dynamic market to deliver sustainable value creation and growth.
We work with pharmaceuticals companies to deliver:
- M&A Strategy, Carve-Outs & Synergy Capture
- Strategic Partnerships, Alliances & Joint Ventures
- Product Innovation & Launch
- Business Unit / Model Re-design
- Market Access
- Supply Chain Operations
- R&D Capabilities and Technology
- Quality and Regulatory Compliance
- Tech Transfer
We assist various pharmaceutical companies, including those focused on:
- Branded & Speciality products
- Generics
- OTC and Consumer Health products
- Contract Research & Manufacturing (CRO, CDMO & CMO)
Disruption in the ACA Market – Implications and Strategic Responses
June 11, 2025
In a recent article, A&M Healthcare Industry Group experts explore key policy changes, market dynamics, stakeholder implications and strategic actions for navigating the evolving landscape surrounding the Affordable Care Act marketplace.
The Effect of Trump’s Tariffs on the European Pharmaceutical and Biopharmaceutical Industry
June 9, 2025
As the U.S. considers imposing tariffs on European pharmaceutical imports, the ripple effects could
be felt across the global healthcare landscape.
FORMER FEDERAL HEALTH MINISTER PROFESSOR GREG HUNT JOINS ALVAREZ & MARSAL AUSTRALIA
May 27, 2025
Alvarez & Marsal appoints The Honourable Greg Hunt as a Senior Advisor bolstering its Healthcare and Public Sector advisories in support of maximizing sustainable value for clients.
Contract Research Organisations M&A Market
March 28, 2025
Rising cost pressures, stricter regulatory demands and advancements in emerging therapeutics are intensifying competition within the industry. These dynamics are fuelling the demand for greater efficiency in development lifecycles, creating significant opportunities for outsourced providers like Contract Research Organisations (CROs).
